|23.70||-0.0400||-0.17%||Vol 70.83K||1Y Perf 28.56%|
|Sep 23rd, 2021 13:44 DELAYED|
|- -%||- -|
|Target Price||34.19||Analyst Rating||Moderate Buy 1.67|
|Potential %||44.44||Finscreener Ranking||★★★ 49.04|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 52.34|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★ 44.55|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||45.11||Earnings Rating||Strong Buy|
|Market Cap||931.55M||Earnings Date||3rd Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd Nov 2021|
|Estimated EPS Next Report||0.05|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||235.70K|
|Avg. Monthly Volume||152.20K|
|Avg. Quarterly Volume||126.26K|
CryoLife Inc. (NYSE: CRY) stock closed at 23.74 per share at the end of the most recent trading day (a 0.72% change compared to the prior day closing price) with a volume of 93.29K shares and market capitalization of 931.55M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 1200 people. CryoLife Inc. CEO is James Patrick Mackin.
The one-year performance of CryoLife Inc. stock is 28.56%, while year-to-date (YTD) performance is 0.55%. CRY stock has a five-year performance of 30.87%. Its 52-week range is between 16.6 and 32.34, which gives CRY stock a 52-week price range ratio of 45.11%
CryoLife Inc. currently has a PE ratio of -77.20, a price-to-book (PB) ratio of 3.12, a price-to-sale (PS) ratio of 3.22, a price to cashflow ratio of 72.50, a PEG ratio of 2.32, a ROA of -1.50%, a ROC of -0.08% and a ROE of -3.76%. The company’s profit margin is -4.07%, its EBITDA margin is 10.90%, and its revenue ttm is $280.26 Million , which makes it $7.13 revenue per share.
Of the last four earnings reports from CryoLife Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.05 for the next earnings report. CryoLife Inc.’s next earnings report date is 03rd Nov 2021.
The consensus rating of Wall Street analysts for CryoLife Inc. is Moderate Buy (1.67), with a target price of $34.19, which is +44.44% compared to the current price. The earnings rating for CryoLife Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CryoLife Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CryoLife Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 8.10, ATR14 : 0.81, CCI20 : -108.65, Chaikin Money Flow : -0.17, MACD : -0.66, Money Flow Index : 31.10, ROC : -7.88, RSI : 37.18, STOCH (14,3) : 24.76, STOCH RSI : 0.74, UO : 43.38, Williams %R : -75.24), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CryoLife Inc. in the last 12-months were: Amy D. Horton (Option Excercise at a value of $225 661), Amy D. Horton (Sold 33 902 shares of value $894 724 ), David Ashley Lee (Option Excercise at a value of $240 960), David Ashley Lee (Sold 50 708 shares of value $1 404 578 ), Dennis B Maier (Option Excercise at a value of $214 293), Dennis B Maier (Sold 15 616 shares of value $395 947 ), James Patrick Mackin (Option Excercise at a value of $465 572), James Patrick Mackin (Sold 45 734 shares of value $1 280 552 ), Jean F. Holloway (Option Excercise at a value of $135 537), Jean F. Holloway (Sold 31 184 shares of value $914 887 ), John E. Davis (Option Excercise at a value of $141 748), John E. Davis (Sold 12 739 shares of value $377 880 ), Ronald D. Mccall (Sold 16 088 shares of value $417 222 ), Scott B. Capps (Option Excercise at a value of $99 700), Scott B. Capps (Sold 8 366 shares of value $178 553 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.